This combination therapy resulted in the marked reduction of TNFR2 expression on tumor-infiltrating Tregs and consequently increases tumor infiltration of interferon-gamma-producing CD8+ CTL (44). The gene discussed is TNFRSF1B; the disease is neoplasm.